Trainee Pearls The EBMT Trainee Committee

Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival. The authors evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study.
https://pubmed.ncbi.nlm.nih.gov/37607457/

ALSO AS VIDEO ON
https://youtu.be/JbHS_-2sJQc

CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari

In this study, Nathanial and colleagues systematically analyzed CD19
CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial
via high-throughput single-cell gene expression and T cell receptor
sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion.
Article: https://www.nature.com/articles/s41591-023-02415-3



As VIDEO on

https://youtu.be/z_aJgRHpEaI

Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments
worldwide. Aina and colleagues assessed the safety and activity of
ARI0002h, a BCMA-targeted CAR T-cell therapy developed by academia, in patients with relapsed or refractory multiple myeloma.
https://pubmed.ncbi.nlm.nih.gov/37414060/

ALSO AS VIDEO ON
https://youtu.be/Ymgg22roWGU

CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari

Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells
that target the disialoganglioside GD2 expressed on tumor cells may be a
therapeutic option for patients with high-risk neuroblastoma. In an
academic, phase 1–2 clinical trial, the investigators enrolled patients
(1 to 25 years of age) with relapsed or refractory, high-risk
neuroblastoma in order to test autologous, third-generation GD2-CAR T
cells expressing the inducible caspase 9 suicide gene (GD2-CART01).
https://www.nejm.org/doi/full/10.1056/NEJMoa2210859

ALSO AS VIDEO ON YOUTUBE

https://youtu.be/o1DVDcrrHFA


CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari

The presence of TP53 mutations is associated with an unfavorable outcome  in patients allografted for acute myeloid leukemia (AML), leading some  to question the benefit of an allogeneic stem cell transplantation  (allo-SCT) for this patient group, although this has not been studied in  a large cohort.  Article: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34268  ALSO AS AUDIO ON
https://podcasts.apple.com/us/podcast/trainee-pearls/id1596786132
https://open.spotify.com/show/2M1PWPZGW9Bz7PL5eh103Y

CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari

Richter transformation (RT) is a paradigmatic evolution of chronic  lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma  conferring a dismal prognosis. The mechanisms driving RT remain largely  unknown.  

Article: https://www.nature.com/articles/s41591-022-01927-8  

ALSO AS AUDIO ON

https://podcasts.apple.com/us/podcast/trainee-pearls/id1596786132 

https://open.spotify.com/show/2M1PWPZGW9Bz7PL5eh103Y  

CONNECT WITH US 

https://twitter.com/TheEBMT_Trainee 

https://www.ebmt.org/trainee-committee

https://twitter.com/CarmeloGurnari